US 11,813,251 B2
Methods of treating gastrointestinal stromal tumors
Rodrigo Ruiz Soto, Waltham, MA (US); Oliver Rosen, Waltham, MA (US); and Jama Pitman, Waltham, MA (US)
Assigned to Deciphera Pharmaceuticals, LLC, Waltham, MA (US)
Filed by Deciphera Pharmaceuticals, LLC, Waltham, MA (US)
Filed on Dec. 30, 2022, as Appl. No. 18/091,743.
Application 17/180,218 is a division of application No. 17/028,640, filed on Sep. 22, 2020, granted, now 10,966,966, issued on Apr. 6, 2021.
Application 18/091,743 is a continuation of application No. 17/735,682, filed on May 3, 2022, granted, now 11,576,904.
Application 17/735,682 is a continuation of application No. 17/727,307, filed on Apr. 22, 2022, granted, now 11,534,432, issued on Dec. 27, 2022.
Application 17/727,307 is a continuation of application No. 17/583,985, filed on Jan. 25, 2022, granted, now 11,344,536, issued on May 31, 2022.
Application 17/583,985 is a continuation of application No. 17/180,218, filed on Feb. 19, 2021, granted, now 11,266,635, issued on Mar. 8, 2022.
Application 17/028,640 is a continuation of application No. PCT/US2020/045876, filed on Aug. 12, 2020.
Claims priority of provisional application 63/023,921, filed on May 13, 2020.
Claims priority of provisional application 63/023,936, filed on May 13, 2020.
Claims priority of provisional application 62/968,927, filed on Jan. 31, 2020.
Claims priority of provisional application 62/968,945, filed on Jan. 31, 2020.
Claims priority of provisional application 62/936,018, filed on Nov. 15, 2019.
Claims priority of provisional application 62/926,281, filed on Oct. 25, 2019.
Claims priority of provisional application 62/904,198, filed on Sep. 23, 2019.
Claims priority of provisional application 62/885,797, filed on Aug. 12, 2019.
Prior Publication US 2023/0145926 A1, May 11, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/4375 (2006.01); A61K 31/4745 (2006.01); A61P 35/00 (2006.01); A61P 9/12 (2006.01)
CPC A61K 31/4375 (2013.01) [A61K 31/4745 (2013.01); A61P 9/12 (2018.01); A61P 35/00 (2018.01)] 4 Claims
 
1. A method of treating a patient suffering from an advanced gastrointestinal stromal tumor with a wild-type KIT mutation, comprising:
orally administering to the patient a 150 mg ripretinib daily or twice daily, wherein the patient has previously been administered three or more kinase inhibitors before administration of the ripretinib, and where one of the previously administered kinase inhibitors is imatinib, and wherein the treatment provides more than 6 months of progression free survival in patients, as determined by mRECIST 1.1, after at least one cycle of 42 days of the daily ripretinib administration.